Teva Parenteral Medicines, Inc. v. U.S. Department of Health and Human Services

CourtDistrict Court, District of Columbia
DecidedOctober 9, 2012
DocketCivil Action No. 2011-0470
StatusPublished

This text of Teva Parenteral Medicines, Inc. v. U.S. Department of Health and Human Services (Teva Parenteral Medicines, Inc. v. U.S. Department of Health and Human Services) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Teva Parenteral Medicines, Inc. v. U.S. Department of Health and Human Services, (D.D.C. 2012).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

TEVA PARENTERAL MEDICINES, INC., et al.,

Plaintiffs, Civil Action No. 11-cv-0470 (RLW) v.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, et al.,

Defendants.

MEMORANDUM OPINION1

Plaintiffs Teva Peranteral Medicines, Inc. (“Teva”) and McKesson Medical-Surgical Inc.

(“McKesson”) filed suit against Defendants U.S. Department of Health and Human Services

(“HHS”) and Kathleen Sebelius in her official capacity as Secretary of Health and Human

Services. Plaintiffs are seeking declaratory and injunctive relief under the Administrative

Procedure Act, 5 U.S.C. §§ 701(a) (“APA”), alleging that the Centers for Disease Control

(“CDC”), a division within HHS, improperly denied Plaintiffs’ request that certain CDC

employees be permitted to give testimony in underlying lawsuits currently pending in Nevada

state court.

1 This unpublished memorandum opinion is intended solely to inform the parties and any reviewing court of the basis for the instant ruling, or alternatively, to assist in any potential future analysis of the res judicata, law of the case, or preclusive effect of the ruling. The Court has designated this opinion as "not intended for publication," but this Court cannot prevent or prohibit the publication of this opinion in the various and sundry electronic and legal databases (as it is a public document), and this Court cannot prevent or prohibit the citation of this opinion by counsel. Cf. Fed. R. App. P. 32.1. Nonetheless, as stated in the operational handbook adopted by our Court of Appeals, “counsel are reminded that the Court's decision to issue an unpublished disposition means that the Court sees no precedential value in that disposition.” D.C. Circuit Handbook of Practice and Internal Procedures 43 (2011). 1

Before the Court are the parties’ cross-motions for summary judgment. For the reasons

set forth below, the Court concludes that the CDC was not arbitrary or capricious in its denial of

Plaintiffs’ request for testimony. Accordingly, the Court shall grant Defendants’ motion for

summary judgment and deny Plaintiffs’ motion for summary judgment.

I. BACKGROUND

Teva and McKeeson are defendants in product liability tort actions filed by hundreds of

litigants in Nevada state court related to a Hepatitis C outbreak that occurred in Clark County,

Nevada between December 2007 and January 2008. In these state court actions, the plaintiffs claim

that they have either contracted Hepatitis C, or have been unnecessarily exposed to the risk of

contracting Hepatitis C, while being anesthetized during endoscopic procedures at clinics in Clark

County, Nevada. Teva and McKesson are the manufacturer and distributor of Propofol, a short-

acting hypnotic agent used in the induction and maintenance of anesthesia employed during these

endoscopic procedures. The plaintiffs in the state court actions have sued Teva and McKesson

under a theory of strict liability, claiming that they were exposed to Hepatitis C when they were

anesthetized using contaminated Propofol vials, and that these vials were unsuitable for use at

endoscopy clinics.

Both the Southern Nevada Health District (“SNHD”) and the CDC investigated the

Hepatitis C outbreak in December 2007 and January 2008. Among the CDC employees involved

in the investigation were Scott Holmberg, Gayle Fischer Langley, Joseph Perz, and Melissa

Scheafer. During these investigations, CDC employees conducted interviews with patients and

medical personnel, collected specimens from patients, reviewed medical records, and observed

medical personnel. In addition, “phylogenetic testing” was conducted in order to identify source

patients.

On May 15, 2008, the CDC released its findings in the Epi-Aid Trip Report (“CDC Trip

Report”). Dkt. No. 18, Ex. 3. The CDC Trip Report disclosed the investigation team’s

methodology, the information gathered, and suggested courses of action. Id. The CDC Trip

Report concluded that some staff routinely reused syringes during individual procedures to

withdraw anesthesia from single-use Propofol vials, and inappropriately used these vials to

provide medication for multiple patients; “[t]his was considered the most likely mode of

[Hepatitis C] transmission.” Id. at 9. In December 2009, SNHD released a separate report

(“SNHD Final Report”) that contained the final results of the SNHD’s two-year investigation.

Dkt. No. 18, Ex. 4. The SNHD Final Report incorporated information from the CDC Trip Report

and concluded that unsafe injection practices and reuse of contaminated Propofol vials were

deemed to be the likely causes of the Hepatitis C infections. Id. at 50.

Because of the allegations lodged against them, Teva and McKesson have sought the

deposition testimony of the CDC employees who investigated the Hepatitis C outbreak. In a letter

dated August 20, 2010, Plaintiffs requested permission from the CDC to depose Scott Holmberg,

Gayle Fischer Langley, Joseph Perz, and Melissa Schaefer in connection with the pending state

court cases. On September 24, 2010, the CDC Director declined Plaintiffs’ request and

determined that the CDC employees would not be made available for deposition. Seeking review

of the CDC’s decision in this Court, Plaintiffs ask the Court to set aside the Defendants’ decision

and issue an injunction compelling the Defendants to permit the depositions sought by plaintiffs.

III. LEGAL STANDARD

Summary judgment is appropriate “if the movant shows [through facts supported in

the record] that there is no genuine dispute as to any material fact and the movant is entitled

to judgment as a matter of law.” Fed. R. Civ. P. 56(a); Anderson v. Liberty Lobby, Inc., 477

U.S. 242, 248 (1986). “The rule governing cross-motions for summary judgment . . . is that

neither party waives the right to a full trial on the merits by filing its own motion; each side

concedes that no material facts are at issue only for the purposes of its own motion.”

Sherwood v. Washington Post, 871 F.2d 1144, 1148 n.4 (D.C. Cir. 1989) (quoting McKenzie

v. Sawyer, 684 F.2d 62, 68 n.3 (D.C. Cir. 1982)).

II. REGULATORY FRAMEWORK

Under the federal “housekeeping statute,” 5 U.S.C. § 301, a federal agency is authorized to

promulgate regulations regarding the disclosure of agency information, including procedures for

responding to requests for documents and testimony by agency employees. See 5 U.S.C. § 301;

see also Touhy v. Ragen, 340 U.S. 462, 469-70 (1951). Regulations promulgated under Section

301 are commonly known as an agency’s Touhy regulations. Truex v. Allstate Ins. Co., 233

F.R.D. 188, 190 (D.D.C. 2006).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Teva Parenteral Medicines, Inc. v. U.S. Department of Health and Human Services, Counsel Stack Legal Research, https://law.counselstack.com/opinion/teva-parenteral-medicines-inc-v-us-department-of-h-dcd-2012.